KA
CRSP icon

Kercheville Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Kercheville Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,245
Closed -$397K – 111
2021
Q4 		$397K Sell
5,245
-1,040
-17% -$90.9K 0.17% 79
2021
Q3 		$703K Buy
6,285
+685
+12% +$86K 0.33% 63
2021
Q2 		$907K Buy
5,600
+95
+2% +$11.6K 0.42% 58
2021
Q1 		$663K Sell
5,505
-15
-0.3% -$2.27K 0.33% 67
2020
Q4 		$848K Buy
+5,520
New +$652K 0.46% 53

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Kercheville Advisors's CRSP Position: Q1 2022 in Review

Kercheville Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2022, closing a stake of 5,245 shares — an estimated $397K sold.

Kercheville Advisors first reported a position in CRSP in Q4 2020 and held it in 5 quarters. The position peaked at $907K in Q2 2021. 447 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

  • Kercheville Advisors reported no remaining CRISPR Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Kercheville Advisors sold 5,245 CRISPR Therapeutics shares in Q1 2022, an estimated $397K.
  • Kercheville Advisors first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 5 quarters.
  • Kercheville Advisors's CRISPR Therapeutics position peaked at $907K in Q2 2021.
  • 447 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on Kercheville Advisors's 13F filing for Q1 2022, filed 29 Apr 2022.